Ed Smith is the Managing Partner of Aristar Capital Management, LLC, a New York-based investment firm. On January 8, 2015, Mr. Smith was appointed Chief Executive Officer of Z Trim Holdings Inc. (OTC:ZTHO), an AgriTech company that has developed new, products and processes to transform biomass for uses in the food and industrial markets. From April 2005 through December 2014, Mr. Smith was the Managing Partner of Brightline Capital Management, LLC ("BCM"), a New York-based investment firm founded in 2005. Prior to founding BCM, Mr. Smith worked at Gracie Capital from 2004-2005, GTCR Golder Rauner from 1999-2001 and Credit Suisse First Boston from 1997-1999. Mr. Smith holds a Bachelor of Arts in Social Studies from Harvard College and a Masters in Business Administration from Harvard Business School. Mr. Smith is also a director of Z Trim Holdings Inc. and Heat Biologics, Inc. (NASDAQ: HTBX), a development stage biopharmaceutical company that focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases.
Jeffrey Wolf is founder and CEO of NightHawk Biosciences. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies founded on breakthrough ideas and technology.
Throughout his career, Mr. Wolf has specialized in building new life-science companies from the ground up and plays an active role in supporting the growth of his companies. Mr. Wolf's start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel biocompatible polymers and acquired by Medtronic; and EluSys Therapeutics (co-founder and founding CEO), a biodefense company focused on the development of Anthim® antibody therapeutic, an approved medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law, and his B.A. from the University of Chicago where he graduated with honors in economics.
Ramon Coronado M.S., Ph.D.
CEO, Pelican Therapeutics
Dr. Ramon Coronado is CEO of Pelican Therapeutics, a subsidiary of Heat Biologics. He previously founded and has successfully served as CEO for other biopharma companies in the cellular and biologics therapeutic industry.
Dr. Ramon Coronado obtained his Polymer Engineering degree from the Simon Bolivar University in Caracas, Venezuela, where he developed a novel thermosensitive hydrogel biomaterial for medical applications; he then obtained his Master and Ph.D. in Biomedical Engineering at the University of Texas at San Antonio, UT Health San Antonio while working at U.S. Army Institute of Surgical Research in San Antonio, Texas. His graduate work and business beginnings were focused on Mesenchymal Stem Cells and immunoregulatory biological therapeutics. He has filed various patents in the biotech field and currently holds adjunct assistant professor positions at Ut Health San Antonio and Baylor College of Medicine.
Dr. Coronado brings over 15 years of experience in the biotech industry, including corporate and business development, management, biologics/cell therapeutics, clinical trials experience, and goal-oriented entrepreneurship.